Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Bio-Rad Laboratories Inc

Healthcare US BIO

291.01USD
-6.16(2.07%)

Last update at 2026-06-10T20:00:00Z

Day Range

290.21298.57
LowHigh

52 Week Range

211.43343.12
LowHigh

Fundamentals

  • Previous Close 297.17
  • Market Cap8253.82M
  • Volume364453
  • P/E Ratio10.98
  • Dividend Yield-%
  • EBITDA431.60M
  • Revenue TTM2583.20M
  • Revenue Per Share TTM94.69
  • Gross Profit TTM 1343.60M
  • Diluted EPS TTM27.85

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 995.50M -2342.50000M -850.10400M -4704.27300M 5438.15M
Minority interest - - - - -
Net income 759.90M -1844.20000M -637.32400M -3627.53500M 4245.90M
Selling general administrative 844.30M 814.00M 846.80M 827.83M 879.57M
Selling and marketing expenses - - - - -
Gross profit 1343.60M 1378.90M 1426.95M 1567.33M 1640.66M
Reconciled depreciation 165.40M 151.60M 144.20M 137.30M 133.80M
Ebit 270.50M -2293.60000M -800.70000M 482.62M 489.43M
Ebitda 475.90M -2142.00000M -654.80000M 664.49M 650.01M
Depreciation and amortization 205.40M 151.60M 145.90M 181.87M 160.58M
Non operating income net other - - - 44.78M 24.02M
Operating income 270.50M 269.00M 337.80M 482.62M 489.43M
Other operating expenses 2317.10M 2297.50M 2333.40M 2319.63M 2433.11M
Interest expense 49.00M 48.90M 49.44M 38.11M 1.55M
Tax provision 235.60M -498.30000M -27.91600M -1076.73800M 1192.25M
Interest income 95.50M 82.00M 96.40M 58.00M 4921.94M
Net interest income 46.50M 33.10M 47.64M 19.89M -1.55100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 235.60M -498.30000M -212.78000M -1076.73800M 1192.25M
Total revenue 2583.20M 2566.50M 2671.26M 2802.25M 2922.55M
Total operating expenses 1077.50M 1109.90M 1089.10M 1084.71M 1151.23M
Cost of revenue 1239.60M 1187.60M 1244.32M 1234.92M 1281.88M
Total other income expense net 725.00M -2611.50000M -1187.90000M -5186.88900M 4948.72M
Discontinued operations - - - - -
Net income from continuing ops 759.90M -1844.20000M -159.29800M -3627.53500M 4245.90M
Net income applicable to common shares 759.90M -1844.20000M -637.32400M -3627.53500M 4245.90M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 10576.50M 9364.10M 12299.07M 13501.67M 17775.79M
Intangible assets 174.30M 293.60M 320.48M 332.15M 253.94M
Earning assets - - - - -
Other current assets 150.30M 153.30M 171.65M 147.78M 117.83M
Total liab 3122.90M 2794.80M 3557.94M 3886.41M 4108.66M
Total stockholder equity 7453.60M 6569.30M 8741.13M 9615.25M 13667.13M
Deferred long term liab - - - 1770.48M 3059.08M
Other current liab 313.50M 271.40M 302.04M 186.20M 210.67M
Common stock 0.00301M 0.00303M 0.00300M 0.00300M 0.00300M
Capital stock 0.00000M 0.00000M 0.00300M 0.00300M 0.00300M
Retained earnings 8176.30M 7416.40M 9260.63M 9898.20M 13507.24M
Other liab - - - 1966.39M 3417.21M
Good will 579.80M 410.50M 413.60M 406.49M 347.34M
Other assets 102.70M 2511.80M - 94.60M 0.08M
Cash 531.80M 488.10M 403.97M 434.21M 470.78M
Cash and equivalents 529.80M 488.10M - 434.21M 470.78M
Total current liabilities 517.00M 467.80M 522.80M 568.71M 680.94M
Current deferred revenue - - 35759.00M 52.21M 50.85M
Net debt 999.20M 886.60M 1001.63M 763.97M -459.78000M
Short term debt 37.90M 42.90M 40.38M 0.47M 0.49M
Short long term debt 1.30M 1.20M 0.49M 0.47M 0.49M
Short long term debt total 1531.00M 1374.70M 1405.44M 1198.18M 11.00M
Other stockholder equity -533.60000M -308.90000M -183.46100M 183.87M 335.44M
Property plant equipment 709.90M 688.60M - 498.61M 695.75M
Total current assets 2906.20M 3030.30M 3048.33M 3157.98M 1989.09M
Long term investments 6103.60M 4839.20M 7698.07M 8830.89M 14387.01M
Net tangible assets - - - 9208.76M 13065.85M
Short term investments 1010.90M 1176.40M 1203.33M 1362.02M 404.69M
Net receivables 472.50M 452.50M 489.02M 494.64M 423.54M
Long term debt 1203.00M 1200.40M 1199.05M 1197.72M 10.51M
Inventory 740.70M 760.00M 780.52M 719.32M 572.24M
Accounts payable 129.00M 122.30M 144.62M 329.83M 418.93M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -189.10000M -538.20000M -336.03800M -466.82200M -175.55300M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00300M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 9898.20M 13507.24M
Treasury stock - - - -263.58600M -106.29000M
Accumulated amortization - - - - -
Non currrent assets other 102.30M 101.90M 94.45M -1770386.40100M -3058977.33100M
Deferred long term asset charges - - - - -
Non current assets total 7670.30M 6333.80M 9250.74M 10343.69M 15786.71M
Capital lease obligations 181.80M 173.10M 205.86M 189.93M 212.37M
Long term debt total 1201.70M 1200.40M - 1197.72M 10.51M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 186.30M -160.20000M -110.54100M -994.21100M -538.17100M
Change to liabilities - - - -1335.80000M 1152.20M
Total cashflows from investing activities -189.70000M -160.20000M - -1207.59300M -784.43800M
Net borrowings -0.50000M -0.40000M - 1185.71M -3.02000M
Total cash from financing activities -283.20000M -218.80000M -425.64700M 973.58M -55.42900M
Change to operating activities - - - -26.80000M 13.93M
Net income 759.90M -1844.20000M -637.32400M -3627.53500M 4245.90M
Change in cash 40.30M 85.40M -30.17500M -36.58900M -195.98200M
Begin period cash flow 489.80M 404.40M 434.54M 471.13M 667.12M
End period cash flow 532.20M 489.80M 404.37M 434.54M 471.13M
Total cash from operating activities 532.20M 455.20M 374.94M 194.45M 656.52M
Issuance of capital stock - - - - -
Depreciation 205.40M 151.60M 192.40M 137.30M 133.80M
Other cashflows from investing activities 793.60M -23.30000M - -100.60000M -658.92200M
Dividends paid - - 100101.00M 68184.00M 35282.00M
Change to inventory 68.90M 8.50M -46.30000M -158.80000M 46.10M
Change to account receivables 19.60M 16.20M 11.40M -87.40000M -20.40000M
Sale purchase of stock -295.50000M -203.60000M -428.72800M -215.67900M -49.99800M
Other cashflows from financing activities -3.00000M -14.80000M 3.55M -212.13400M -2.41100M
Change to netincome - - - 5254.73M -3776.37800M
Capital expenditures 157.60M 189.00M 156.68M 114.16M 120.80M
Change receivables - - - 68.18M 35.28M
Cash flows other operating - - - 126.26M 621.24M
Exchange rate changes - - - - -12.63600M
Cash and cash equivalents changes - - - -39.57000M -195.98200M
Change in working capital 275.60M -620.80000M -127.63300M -407.03800M 13.93M
Stock based compensation 58.00M 62.30M 61.30M 60.90M 51.20M
Other non cash items -879.20000M 2706.30M 1078.60M 5272.42M -3737.11400M
Free cash flow 374.60M 266.20M 218.26M 80.29M 535.72M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BIO
Bio-Rad Laboratories Inc		 -6.16 2.07% 291.01 10.98 30.21 3.20 1.11 3.08 6.58
ABT
Abbott Laboratories		 -2.08 2.28% 89.17 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 -5.17 1.65% 308.84 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -1.73 2.11% 80.25 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.62 1.27% 48.34 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Inc

1000 Alfred Nobel Drive, Hercules, CA, United States, 94547

Key Executives

Name Title Year Born
Mr. Norman D. Schwartz Chairman, CEO & Pres 1950
Mr. Ilan Daskal Exec. VP & CFO 1966
Dr. Andrew J. Last Ph.D. Exec. VP & COO 1960
Mr. Michael Crowley Exec. VP of Global Commercial Operations 1962
Ms. Dara Grantham Wright Exec. VP & Pres of Clinical Diagnostics Group 1976
Mr. Ajit Ramalingam Sr. VP & Chief Accounting Officer 1973
Mr. Yong Chung VP of Investor Relations NA
Mr. Timothy S. Ernst Exec. VP, Gen. Counsel & Sec. 1960
Colleen Corey Sr. VP of Global HR NA
Lee Boyd Sr. VP of Global Commercial Operations - Asia Pacific NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.